ALUMIS INC.
Close on Oct 19, 2026
- Market cap
- $809.56M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | During market hours | $1.70M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | During market hours | $1.70M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 19, 2026 | During market hours | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | During market hours | $2.10M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | During market hours | $2.70M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | During market hours | $17.40M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 19, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | During market hours | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | During market hours | – | – | – |
Press releases
Announcements Alumis filed with the SEC
Alumis Announces Topline Results from Envudeucitinib
Other events · EX-99.1 to Form 8-K
Transform Therapies. Reimagine Lives. LUMUS Phase 2b Topline Results September 1, 2026
Other events · EX-99.2 to Form 8-K
Alumis Reports Second Quarter 2026 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Envudeucitinib Long-term Data Positioned to
Other events · EX-99.1 to Form 8-K
Alumis Reports First Quarter 2026 Financial Results and
Results of operations · EX-99.1 to Form 8-K
and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as
Other events · EX-99.1 to Form 8-K
Envudeucitinib (ESK-001) in Moderate-to-Severe Plaque
Other events · EX-99.2 to Form 8-K
Alumis Reports Year End 2025 Financial Results and Highlights
Results of operations · EX-99.1 to Form 8-K
Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program
Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Other events · EX-99.2 to Form 8-K
Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
Results of operations · EX-99.1 to Form 8-K
Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Alumis Completes Merger with ACELYRIN
Acquisition or disposition completed · Executive or director change · Other events · EX-99.1 to Form 8-K
Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements
Results of operations · EX-99.1 to Form 8-K
Alumis and ACELYRIN Announce Amended Merger
Material agreement · Other events · EX-99.1 to Form 8-K
Alumis and Kaken Pharmaceutical Announce Collaboration
Other events · EX-99.1 to Form 8-K
Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements
Results of operations · EX-99.1 to Form 8-K
Transform Therapies. Reimagine Lives. March 2025 Corporate Presentation Supplemental Materials
Other events · EX-99.1 to Form 8-K
Late-Breaking ESK-001 Phase 2 OLE Data Presented
Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Other events · EX-99.2 to Form 8-K
Alumis and ACELYRIN Reaffirm Strategic and
Regulation FD disclosure · EX-99.1 to Form 8-K
and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to
Material agreement · Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Transform Therapies. Reimagine Lives. February 6, 2025 Alumis and ACELYRIN Merger Investor Presentation |
Material agreement · Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
AGREEMENT (this “ Agreement ”) is made and entered into as of February 6, 2025, by and among ACELYRIN, Inc.,
Material agreement · Results of operations · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements
Results of operations · EX-99.1 to Form 8-K
Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements
Results of operations · EX-99.1 to Form 8-K